Expect Malaysian unit to contribute 3/4th of insulin biz revenue going ahead: Biocon

Small booster for Biocon as they have received a certificate of good manufacturing practices (GMP) compliance from the European regulator for its insulin manufacturing facility in Malaysia.

In an interview to CNBC-TV18, Kiran Mazumder Shaw, CMD of Biocon spoke about the same and latest happenings in the company.

Mazumder Shaw said Malaysian facility is one of Biocon's largest insulin units.

GMP certificate from EU regulator is with regards to insulin Glargine application that was submitted to European Medicines Agency (EMA).

On US FDA front, she expects the US Food and Drug Administration (US FDA) inspection for Malaysian plant in near future.

She also expects Malaysian unit to contribute three-fourth of insulin business revenue going ahead.

Biocon is focussing on advancing oral insulin programme, IN-105.

Watch accompanying video for more details.